Smith & Nephew Pays $240M For Integra’s Extremities Business
Integra is divesting its underperforming extremity orthopedics product portfolio to focus on its neurosurgery, surgical instrument and regenerative medicine businesses.
You may also be interested in...
The resurgence of the pandemic during the fourth quarter of 2020 led to slowdown in elective procedures, negatively impacting sales of the four big ortho players.
Despite COVID-19, the market for extremity replacement implants looks healthy in the medium-term, with strong growth predicted as elective surgeries return.
Led by the Mako surgical robot, Stryker’s third-quarter sales exceeded Wall Street analysts’ expectations as it prepares to complete the $4bn acquisition of Wright Medical.